- Home
- KPTI vs MREO Comparison
KPTI vs MREO Comparison
Compare KPTI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | MREO |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 50.3M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KPTI | MREO |
|---|---|---|
| Price | $1.60 | $0.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $16.00 | $1.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | $22.36 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.65 | $0.20 |
| 52 Week High | $10.99 | $2.37 |
Technical Indicators
Market Signals| Indicator | KPTI | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 25.29 | 35.49 |
| Support Level | N/A | $0.22 |
| Resistance Level | $2.16 | $0.35 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 3.67 | 11.89 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).